• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

InfuSystem, Ventis Pharma enter pain management marketing deal

June 14, 2022 By Sean Whooley

InfuSystem - updated logoInfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma.

Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine.

Ventis Pharma designed its innovative, long-acting, very low-toxicity products to reduce surgical pain and treat chronic pain conditions safely and effectively. InfuSystem said in a news release that healthcare providers are increasingly turning to such multi-modal pain management approaches.

“We are pleased to partner with Ventis Pharma in providing a complementary pain management solution,” InfuSystem CEO Richard DiIorio said in the release. “Endura-Kit can be used in conjunction with our InfuBLOCK or as a standalone treatment – providing healthcare professionals and patients an exceptional alternative to oral opioid painkillers. The opioid epidemic in North America is a serious health care crisis. InfuSystem and Ventis Pharma are fully committed to doing our part in helping to reduce the use of oral opioids.”

DiIorio added that he believes the agreement provides InfuSystem’s sales team with “an exciting product” that expands the company’s offerings to its customers, generates additional revenue stream and enhances the effectiveness of each sales call, creating what he expects to be a mutually beneficial relationship.

“Endura-Kit provides anesthesiologists, surgeons and CRNAs with a better option than the current non-opioid post-op local anesthetic products currently available in the market,” Ventis Pharma CEO Tim Patrick said. “We look forward to working closely with InfuSystem and are excited to provide our products and services to our mutual healthcare customers and their patients. This partnership illustrates our unwavering commitment to delivering better medicine to more people while improving the patient’s healthcare experience.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: infusystem, Ventis Pharma

IN CASE YOU MISSED IT

  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS